Skip to main content
. 2022 Sep 23;8(38):eabo6638. doi: 10.1126/sciadv.abo6638

Fig. 2. VLDL-mimicking and integrin-addressing NLCs target RPE and endothelial cells.

Fig. 2.

(A) Schematic illustration of the VLDL-mimicking nanocapsule composition and the heteromultivalent targeting concept of RGD-LNCs. (B) Hydrodynamic diameter and polydispersity index (PDI) of LNCs and RGD-LNCs. (C) ς potential of LNCs and RGD-LNCs. (D) Ligand-mediated cellular uptake of LNCs and RGD-LNCs in human RPE (ARPE) cells and human dermal microvascular endothelial (HDME) cells, partially inhibited by free cRGD. (E) Ligand-mediated uptake kinetic of LNCs and RGD-LNCs in ARPE cells. (F) Cellular localization of LNCs and RGD-LNCs in HDME and ARPE cells. Scale bars, 20 μm. Results are presented as means ± SD of n = 10 (B and C) independent experiments and n = 3 (D and E) biologically independent samples per group. Levels of statistical significance are indicated as ****P ≤ 0.0001. n.s., nonsignificant. P values were determined by two-way analysis of variance (ANOVA) (D) and one-way ANOVA (E). DAPI, 4′,6-diamidino-2-phenylindole.